Journal club: Durvalumab as Consolidation therapy in Advanced NSCLC
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial - Journal of Thoracic Oncology
Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▽, AstraZeneca UK Limited) | British Journal of Cancer
Immunotherapy: analyses elucidating durvalumab & pembrolizumab activity - memoinOncology
PDF) PACIFIC: Overall Survival with Durvalumab versus Placebo after Chemoradiotherapy in Stage III NSCLC
New data on PD-L1 inhibitor activity and determinants of outcomes in immunotherapy-treated patients - memoinOncology
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC | NEJM
Implementation of durvalumab maintenance treatment after concurrent chemoradiotherapy in inoperable stage III non-small cell lung cancer (NSCLC)—a German radiation oncology survey - Käsmann - Translational Lung Cancer Research
Durvalumab Improves Overall Survival in NSCLC After Chemoradiotherapy - Onco Americas
Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC - Journal of Thoracic Oncology
PDF) Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▽, AstraZeneca UK Limited)
Innovación en terapia sistémica de cáncer de pulmón
PDF) PACIFIC: Overall Survival with Durvalumab versus Placebo after Chemoradiotherapy in Stage III NSCLC
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC | NEJM
PDF) Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC | Semantic Scholar
Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study - Lung Cancer
Stage Iii Lung Cancer Durvalumab
Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial - Annals of Oncology
Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial - Annals of Oncology
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial - Journal of Thoracic Oncology
Stage III NSCLC Clinical Trials & Efficacy Data for IMFINZI® (durvalumab)
